Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology,

Zhicheng Deng1,2, Guanghui Chen1, Yonghui Shi1

  • 1Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Insights

Curcumin (CUR) and its nano-formulation (CUR-NPs) show promise in treating triple-negative breast cancer (TNBC) by inhibiting multiple targets and pathways. This study elucidates CUR

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • Curcumin (CUR) exhibits anti-cancer properties, but its mechanisms against triple-negative breast cancer (TNBC) require detailed investigation.
  • Triple-negative breast cancer (TNBC) remains a challenging subtype with limited targeted therapies.

Purpose of the Study:

  • To elucidate the pharmacological actions and underlying mechanisms of Curcumin (CUR) against triple-negative breast cancer (TNBC) using a multi-modal approach.
  • To evaluate the efficacy of Curcumin (CUR) and its nano-formulation (CUR-NPs) against TNBC cells.

Main Methods:

  • A combination of network pharmacology, molecular docking, and in vitro bio-experiments was employed.
  • Target identification involved public databases, Venn diagrams, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment.
  • Protein-protein interaction networks, molecular docking, and in vitro assays (cell proliferation, migration, invasion, apoptosis, real-time PCR, Western blot) were utilized.

Main Results:

  • Forty potential targets for CUR against TNBC were identified, with STAT3, AKT1, and TNF among the top 10.
  • Curcumin (CUR) and CUR-NPs demonstrated significant inhibition of MDA-MB-231 cell proliferation, migration, and invasion, while inducing apoptosis.
  • Molecular docking confirmed CUR's binding affinity to top targets, and experiments showed downregulation of target gene expression and inhibition of the JAK-STAT pathway.

Conclusions:

  • Curcumin (CUR) and its nano-formulation (CUR-NPs) possess significant pharmacological effects against triple-negative breast cancer (TNBC).
  • These effects are mediated through a multi-target and multi-pathway mechanism, including the JAK-STAT signaling pathway.
  • The findings support the potential of CUR and CUR-NPs as therapeutic agents for TNBC.